DelveInsight’s ‘Primary Hyperoxaluria (PH) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Primary Hyperoxaluria (PH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Primary Hyperoxaluria (PH) - Disease Understanding and Treatment Algorithm
The DelveInsight Primary Hyperoxaluria (PH) market report gives the thorough understanding of the Primary Hyperoxaluria (PH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Primary Hyperoxaluria (PH) in the US, EU5, and Japan.
Primary Hyperoxaluria (PH) Epidemiology
The Primary Hyperoxaluria (PH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, Type specific diagnosed prevalent cases (PH Type 1, 2, 3 & unclassified) and Age-Specific diagnosed prevalent cases) scenario of Primary Hyperoxaluria (PH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of diagnosed prevalent population of Primary Hyperoxaluria (PH) was found to be 3,714, in the year 2016.
Primary Hyperoxaluria (PH) Drug Chapters
This segment of the Primary Hyperoxaluria (PH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, there is no FDA approved therapy for the treatment of Primary Hyperoxaluria in the United States and the current therapeutic market for Primary Hyperoxaluria is based on the therapies such as Enzyme reactivation therapy, Gene therapies and Substrate reduction therapy through RNA-interference. Treatment options for primary hyperoxaluria include alkaline citrate, orthophosphate, or magnesium. Upcoming therapies such as Oxabact (OxThera), ALLN-177 (Allena Pharmaceuticals) and Lumasiran (Alnylam Pharmaceuticals), have the potential to create a significant positive shift in the Primary Hyperoxaluria market size.
Primary Hyperoxaluria (PH) Market Outlook
The Primary Hyperoxaluria (PH) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Primary Hyperoxaluria (PH) in 7MM was found to be USD 330.58 million in 2016.
Primary Hyperoxaluria (PH) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Primary Hyperoxaluria (PH) Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Primary Hyperoxaluria (PH) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Primary Hyperoxaluria (PH) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Primary Hyperoxaluria (PH) market
• Organize sales and marketing efforts by identifying the best opportunities for Primary Hyperoxaluria (PH) market
• To understand the future market competition in the Primary Hyperoxaluria (PH) market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook